In a report released today, Chad Messer from Needham maintained a Buy rating on Athersys (ATHX), with a price target of $5.00. The company’s shares closed last Thursday at $1.56, close to its 52-week low of $1.51.
According to TipRanks.com, Messer is a 4-star analyst with an average return of 5.3% and a 42.2% success rate. Messer covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Phasebio Pharmaceuticals, and Aeglea Biotherapeutics.
Currently, the analyst consensus on Athersys is a Moderate Buy with an average price target of $6.00.
See today’s analyst top recommended stocks >>
Athersys’ market cap is currently $344.5M and has a P/E ratio of -3.80. The company has a Price to Book ratio of 11.12.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.
